Investors

We are proud to play an active role in today's medicine, collaboratively seeking to provide innovative and meaningful solutions for relevant medical problems. You as an investor want to understand how we intend to achieve our ambitious goals. If you need any further information, besides what you find on our website, please do not hesitate to reach out to us.

News

Stock Info

Nymox Pharmaceutical Corp
NASDAQ: NYMX

0.32 USD

>> Detailed stock information

 

Press Releases

March 27, 2024
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages

December 27, 2023
Nymox December 27 Message to Shareholders

November 30, 2023
Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others

>> All press releases

Corporate

Team

Dr. Paul Averback is the founder, CEO and President of Nymox. Dr. Averback has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Facutly member.

More about our team

Financial Information

>> Annual reports

>> SEC filings

>> Corporate governance

Science

Research strategy

Nymox has rights to several hundred patents and patent applications through the world covering a wide range of scienfitic and medical fields, technologies and applications.

>> More about our research strategy

Pipeline

Nymox is working hard on developing and introducing simple solutions to meet the huge unmet medical need to efficacious, safe and simple treatment options.

>> More about our research pipeline

Products